Aktywnosc in vitro cefepimu wobec ESBL-dodatnich klinicznych szczepow Gram-ujemnych paleczek

• Autorzy: Rokosz A. , Sawicka-Grzelak A. , Luczak M.

Warianty tytułu

EN

In vitro activity of cefepime against ESBL-positive clinical strains of Gram-negative rods

• Języki publikacji: PL

Abstrakty

PL

Przedmiotem badań było 100 ESBL-dodatnich szczepów Gram-ujemnych pałeczek wyizolowanych z przypadków zakażeń u hospitalizowanych pacjentów. Oznaczono wrażliwość in vitro tych szczepów na cefalosporynç IV generacji - cefepim. Zastosowano gradientowo-dyfuzyjną metodę Etest. Wśród badanych szczepów 14 bylo wrażliwych, 12 - średniowrażliwych i 74 - opornych na cefepim.

EN

The aim of this study was to determine an in vitro activity of cefepime against ESBL-positive clinical strains of Gram-negative rods isolated from hospitalized patients. Experiments were performed with 100 ESBL-positive strains of Gram-negative rods isolated from clinical samples in 2004. Strains were identified with the use of automatic ATB Expression system and biochemical ID 32 GN tests (bioMérieux® sa). Extended-spectrum beta-lactamases (ESBLs) were detected by means of disc diffusion methods: the double-disc synergy test (DDST) and the diagnostic disc test (DD, Oxoid Ltd, UK). Susceptibility in vitro of ESBL producers to 4th generation - cefepime was determined with gradient diffusion method Etest (AB Biodisk, Solna, Sweden). MIC value of cefepime was assessed for each strain. Among 100 ESBL-producing strains, 94 - belonged to enteric rods and б - to nonfermentative rods. The greatest number of strains belonged to the species Serratia marcescens (27% of all strains) and next - to the species Enterobacter cloacae (21%). Fourteen strains were susceptible (S) in vitro to cefepime, 12 - intermediately susceptible (I) and 74 - resistant (R). Application of cefepime in a therapy of infections caused by ESBL-positive strains of Gram- negative rods highly susceptible in vitro to this antibiotic, should be considered.

Słowa kluczowe

PL

szczepy bakteryjne; wrazliwosc na antybiotyki; pacjenci; opornosc na antybiotyki; bakterie Gram-ujemne; antybiotyki; cefepim; dzialanie bakteriobojcze; metoda Etest

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2005
• Tom: 57
• Numer: 4
• Opis fizyczny: s.409-416,tab.,bibliogr.

Twórcy

autor

Rokosz A.

• Akademia Medyczna w Warszawie, ul.T.Chalubinskiego 5, 02-004 Warszawa

autor

Sawicka-Grzelak A.

autor

Luczak M.

Bibliografia

• 1. Appleton A. Evaluation of a novel Diagnostic Disc method for detection of extended-spectrum ß-lactamases. J Antimicrob Chemother 1999; 44(Suppl A): 67.
• 2. Bedenic B, Beader N, Zagar Z. Effect of inoculum size on the bacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended spectrum beta-lactamases. Clin Microbiol Infect 2001; 7: 626-35.
• 3. Blahova J, Hupkova-Lesicka M, Kralikova K i inni. The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer. Cas Lek Cesk 1997; 136; 154-6.
• 4. Chastagner P, Plouvier E, Eyer D i inni. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer. Med Pediatr Oncol 2000; 34: 306-8.
• 5. Coudron PE, Hanson ND, Climo MW. Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases. J Clin Microbiol 2003; 41: 772-7.
• 6. Dzierżanowska D. Antybiotykoterapia praktyczna. Alfa-medica press, Bielsko-Biała 2000.
• 7. Essack SY. Treatment options for extended-spectrum beta-lactamase. FEMS Microbiol Lett 2000; 190: 181-4.
• 8. Finch RG, Greenwood D, Norrby SR, Whitley RJ. Antibiotic and Chemotherapy. Anti-infective agents and their use in therapy. Churchill Livingstone, Edinburgh, London, New York, Philadelphia, St Louis, Sydney, Toronto 2003.
• 9. Jandula BM, Martino R, Gurgi M i inni. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy 2001; 47: 226-31.
• 10. Jarlier V, Nicolas MH, Foumier G, Philippon A. Extended broad-spectrum b-lactamases conferring transferable resistance to newer ß-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
• 11. Johnson CC, Livornese L, Gold MJ i inni. Activity of cefepime against ceftazidime-resistant gram- negative bacilli using low and high inocula. J Antimicrob Chemother 1995; 35: 765-73.
• 12. Livermore DM. ß-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
• 13. Lozniewski A, Lion C, Mory F, Weber M. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother 2001; 47: 83-6.
• 14. Matysiak M. Empiryczna antybiotykoterapia u gorączkujących chorych w neutropenii. Zakażenia 2004; 4(1): 18-24.
• 15. Młynarczyk A, Łuczak M. Cefalosporyny IV generacji. Zakażenia 2004; 4(2): 23-7.
• 16. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing - 13th Informational Supplement. NCCLS Ml 00-S13, Wayne, Pa, 2003.
• 17. Poirel L, Heritier C, Podglajen I i inni. Emergence of Klebsiella pneumoniae of a chromosome- encoded SITV beta-lactamase that compromises the efficacy of imipenem. Antimicrob Agents Chemother 2003; 47: 755-8.
• 18. Queenan AM, Foleno B, Gownley C i inni. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42: 269-75.
• 19. Rokosz A, Sawicka-Grzelak A. Występowanie beta-laktamaz o rozszerzonym spektrum substratowym (ESBL) i beta-laktamaz indukowanych (IBL) u klinicznych szczepów pałeczek Gram-ujemnych. Med Dośw Mikrobiol 1998; 50: 31-9.
• 20. Rokosz A, Sawicka-Grzelak A, Mészáros J, Łuczak M. Zastosowanie nowej metody do wykrywania beta-laktamaz o rozszerzonym spektrum substratowym (ESBLs). Med Dośw Mikrobiol 2002; 54: 225-31.
• 21. Rokosz A, Sawicka-Grzelak A, Łuczak M. Zastosowanie czterech wariantów testu krążka diagnostycznego (CD01, CD02, CD03, CD04) do wykrywania ESBL-dodatnich szczepów Gram-ujemnych pałeczek. Med Dośw Mikrobiol 2005; 57: 77-83.
• 22. Sawicka-Grzelak A, Rokosz A, Mielczarczyk J i inni. Activity of cefepime against ESBL-producing enteric and non-fermenting rods. Int J Antimicrob Agents 2001; 17(Suppl 1): S128.
• 23. Silva J, Aguilar C, Estrada MA i inni. Susceptibility to new beta-lactams of enterobacterial extended-spectrum beta-lactamase (ESBL) producers and penicillin-resistant Streptococcus pneumoniae in Mexico. J Chemother 1998; 10: 102-7.
• 24. Soriano F, Garcia-Corbeira P, Ponte C i inni. Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother 1996; 40:2686-90.
• 25. Spanu T, Luzzaro F, Perilli M i inni. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46: 196-202.
• 26. Toltzis P, Dul M, O 'Riordan MA i inni. Cefepime use in a pediatric intensive care unit reduces colonization with resistant bacilli. Pediatr Infect Dis J 2003; 22: 109-14.